14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis

Abstract Background Accelerated atherosclerosis is a common health insult in rheumatoid arthritis (RA) patients. Pro-inflammatory cytokines, endothelial dysfunction, and autoantibodies participate in the progression of RA-related atherosclerosis. Novel biomarkers may help early detection of subclini...

Full description

Saved in:
Bibliographic Details
Main Authors: Sahar A. Elsayed, Doaa Adel, Mohammed Zaki, Eman A. M. Alkady
Format: Article
Language:English
Published: SpringerOpen 2025-03-01
Series:Egyptian Rheumatology and Rehabilitation
Subjects:
Online Access:https://doi.org/10.1186/s43166-025-00311-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850028114134958080
author Sahar A. Elsayed
Doaa Adel
Mohammed Zaki
Eman A. M. Alkady
author_facet Sahar A. Elsayed
Doaa Adel
Mohammed Zaki
Eman A. M. Alkady
author_sort Sahar A. Elsayed
collection DOAJ
description Abstract Background Accelerated atherosclerosis is a common health insult in rheumatoid arthritis (RA) patients. Pro-inflammatory cytokines, endothelial dysfunction, and autoantibodies participate in the progression of RA-related atherosclerosis. Novel biomarkers may help early detection of subclinical atherosclerosis and represent new therapeutic targets. We aimed to assess serum 14–3-3 eta (η) protein in RA patients and to explore its relation to radiological joint damage and subclinical atherosclerosis after excluding traditional risk factors for atherosclerosis. Results The patients have increased serum 14–3-3 η protein and carotid intima-media thickness (CIMT) compared to the controls. The serum 14–3-3 η protein in our patients was positively correlated with age, disease duration, Larsen score, Rt-CIMT, Lt-CIMT, mean CIMT, C reactive protein (CRP), and Anti-citrullinated protein antibodies (ACPA). At a 31.05 ng/ml cut-off value, 14–3-3 η protein had 86.7% sensitivity and 84% specificity for RA. At a 45.7 ng/ml cut-off value, 14–3-3 η protein had 70.3% sensitivity and 79.2% specificity for the CIMT. Conclusion 14–3-3 η protein may be a valuable prognostic marker for RA. It positively correlates with the Larsen score and thus may serve as a marker for joint damage. In addition, it may be a promising marker reflecting subclinical atherosclerosis comorbidity in RA patients even without clinical signs of atherosclerosis, as it positively correlates with CIMT with high sensitivity and specificity.
format Article
id doaj-art-12fd5b83ad2d41ea933a8456b36fd8ea
institution DOAJ
issn 2090-3235
language English
publishDate 2025-03-01
publisher SpringerOpen
record_format Article
series Egyptian Rheumatology and Rehabilitation
spelling doaj-art-12fd5b83ad2d41ea933a8456b36fd8ea2025-08-20T02:59:54ZengSpringerOpenEgyptian Rheumatology and Rehabilitation2090-32352025-03-015211910.1186/s43166-025-00311-x14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosisSahar A. Elsayed0Doaa Adel1Mohammed Zaki2Eman A. M. Alkady3Sohag UniversitySohag UniversitySohag UniversityAssiut UniversityAbstract Background Accelerated atherosclerosis is a common health insult in rheumatoid arthritis (RA) patients. Pro-inflammatory cytokines, endothelial dysfunction, and autoantibodies participate in the progression of RA-related atherosclerosis. Novel biomarkers may help early detection of subclinical atherosclerosis and represent new therapeutic targets. We aimed to assess serum 14–3-3 eta (η) protein in RA patients and to explore its relation to radiological joint damage and subclinical atherosclerosis after excluding traditional risk factors for atherosclerosis. Results The patients have increased serum 14–3-3 η protein and carotid intima-media thickness (CIMT) compared to the controls. The serum 14–3-3 η protein in our patients was positively correlated with age, disease duration, Larsen score, Rt-CIMT, Lt-CIMT, mean CIMT, C reactive protein (CRP), and Anti-citrullinated protein antibodies (ACPA). At a 31.05 ng/ml cut-off value, 14–3-3 η protein had 86.7% sensitivity and 84% specificity for RA. At a 45.7 ng/ml cut-off value, 14–3-3 η protein had 70.3% sensitivity and 79.2% specificity for the CIMT. Conclusion 14–3-3 η protein may be a valuable prognostic marker for RA. It positively correlates with the Larsen score and thus may serve as a marker for joint damage. In addition, it may be a promising marker reflecting subclinical atherosclerosis comorbidity in RA patients even without clinical signs of atherosclerosis, as it positively correlates with CIMT with high sensitivity and specificity.https://doi.org/10.1186/s43166-025-00311-xRheumatoid arthritisLarsen scoreSubclinical atherosclerosis14–3-3 η protein
spellingShingle Sahar A. Elsayed
Doaa Adel
Mohammed Zaki
Eman A. M. Alkady
14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
Egyptian Rheumatology and Rehabilitation
Rheumatoid arthritis
Larsen score
Subclinical atherosclerosis
14–3-3 η protein
title 14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
title_full 14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
title_fullStr 14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
title_full_unstemmed 14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
title_short 14–3-3 eta (η) protein as a promising marker for rheumatoid arthritis: relation to joint damage and subclinical atherosclerosis
title_sort 14 3 3 eta η protein as a promising marker for rheumatoid arthritis relation to joint damage and subclinical atherosclerosis
topic Rheumatoid arthritis
Larsen score
Subclinical atherosclerosis
14–3-3 η protein
url https://doi.org/10.1186/s43166-025-00311-x
work_keys_str_mv AT saharaelsayed 1433etaēproteinasapromisingmarkerforrheumatoidarthritisrelationtojointdamageandsubclinicalatherosclerosis
AT doaaadel 1433etaēproteinasapromisingmarkerforrheumatoidarthritisrelationtojointdamageandsubclinicalatherosclerosis
AT mohammedzaki 1433etaēproteinasapromisingmarkerforrheumatoidarthritisrelationtojointdamageandsubclinicalatherosclerosis
AT emanamalkady 1433etaēproteinasapromisingmarkerforrheumatoidarthritisrelationtojointdamageandsubclinicalatherosclerosis